Goat anti-Human IgG Fc Secondary Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NB7446
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Concentration
Product Specifications
Immunogen
Specificity
Clonality
Host
Isotype
Description
Scientific Data Images for Goat anti-Human IgG Fc Secondary Antibody
Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446]
Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - A) Kidney from control did not show any specific staining in the glomeruli. Only erythrocytes (arrow) showed weak fluorescence. B) 1 day: endothelium & material within the capillaries of a glomerulus were highly fluorescent (white arrow). In an adjacent glomerulus, only the endothelium was stained (white arrowhead) not for the lumina of the vessels (black arrow). C) Erythrocytes (arrowhead) and endothelium (arrow). D) 7 days: fluorescence within the capillaries (arrowhead) & endothelium was weaker. E) 1 day after ranibizumab injection, the endothelium cell layer (white arrow) and erythrocytes (arrowhead and black arrow) were fluorescent. F) The fluorescence (arrowhead) was nearly lost 7 days after injection. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0113701) licensed under a CC-BY license.Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446]
Western Blot: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Image from verified customer review. Image using the HRP form of this antibody.Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] -
Immunohistochemistry: Goat anti-Human IgG Fc Secondary Antibody [NB7446] - Immune fluorescent photomicrographs of glomeruli from control (A), aflibercept-treated (B–D) & ranibizumab-treated (E–F) monkeys eyes.In all figures, the asterisks label the spaces of the Bowman capsule. A) Kidney sections from the control animal did not show any specific staining with anti-human IgG-Fc antibody in the glomeruli. Only the erythrocytes (arrow) within the capillaries showed a weak fluorescence. B) One day after aflibercept injection, the endothelium cell layer & material within the capillaries of a glomerulus were highly fluorescent (white arrow) after labelling with an antibody against the Fc region of IgG. In an adjacent glomerulus, only the endothelium was stained (white arrowhead) whereas the lumina of the vessels did not contain IgG-Fc positive material (black arrow). C) Erythrocytes within the glomeruli (arrowhead) as well as the endothelium (arrow) were highly fluorescent. D) Seven days after aflibercept injection, the fluorescent material within the capillaries (arrowhead) & the fluorescence intensity of the endothelium became weaker. E) One day after ranibizumab injection, the endothelium cell layer (white arrow) & erythrocytes (arrowhead & black arrow in the inset) were fluorescent after staining with an antibody against human Fab of IgG. F) The specific fluorescence of the endothelium (arrow) & erythrocytes (arrowhead) was nearly lost seven days after injection of ranibizumab. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25415380), licensed under a CC-BY license. Not internally tested by Novus Biologicals.Applications for Goat anti-Human IgG Fc Secondary Antibody
Electron Microscopy
Immunocytochemistry/ Immunofluorescence
Immunohistochemistry
Immunohistochemistry-Paraffin
Western Blot
Reviewed Applications
Read 1 review rated 5 using NB7446 in the following applications:
Formulation, Preparation, and Storage
Purification
Formulation
Preservative
Concentration
Shipping
Stability & Storage
Background: IgG Fc
Additional IgG Fc Products
Product Documents for Goat anti-Human IgG Fc Secondary Antibody
Product Specific Notices for Goat anti-Human IgG Fc Secondary Antibody
Antiserum was solid phase adsorbed to ensure class specificity. The antibody was isolated by affinity chromatography using antigen coupled to agarose beads. Antibody concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG. By immunoelectrophoresis and ELISA this antibody reacts specifically with human IgG. Cross reactivity with IgA, IgM and light chains is less than 0.1%. This antibody may cross react with IgG from other species.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Secondary Antibodies are guaranteed for 1 year from date of receipt.